Cargando…
CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion
Dendritic cells (DCs) are potent antigen-presenting cells and critical for the priming of CD8+ T cells. Therefore the use of these cells as adjuvant cells has been tested in a large number of experimental and clinical vaccination studies, in particular cancer vaccine studies. A number of protocols a...
Autores principales: | Pedersen, Anders E, Ronchese, Franca |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950502/ https://www.ncbi.nlm.nih.gov/pubmed/17662155 http://dx.doi.org/10.1186/1476-8518-5-9 |
Ejemplares similares
-
S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014) -
DNA is an efficient booster of dendritic cell-based vaccine
por: Li, Jinyao, et al.
Publicado: (2015) -
Adoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression
por: Yee, Cassian, et al.
Publicado: (2014) -
CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk
por: Mayer, Edda, et al.
Publicado: (2013) -
Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8(+) T Cells Independently of CD4(+)T Cell Help
por: McCoy, Kathy D., et al.
Publicado: (1999)